title: Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
abstract: Bortezomib was the first antineoplastic proteasome inhibitor and is currently indicated for the treatment of hematologic malignancies including multiple myeloma and mantle cell lymphoma. This report describes a 57-year-old patient with light chain (primary) amyloidosis receiving weekly subcutaneous bortezomib injections who presented with recurrent hypoxemia and interstitial pneumonitis. Following the failure of conventional therapy, the patient responded rapidly to high-dose intravenous methylprednisolone. Oxygen therapy was able to be weaned off within three days and he was able to be discharged to home in stable condition, with follow-up computed tomography showing improving lung lesions. Bortezomib is known to rarely cause acute lung injury, but this complication has not been previously described in the setting of amyloidosis. Clinicians should be aware of potentially severe pulmonary adverse effects in all patients treated with bortezomib.
authors.forename: Erich
authors.initials: E
authors.lastname: Balsman
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000069286:Bortezomib / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D000075363:Immunoglobulin Light-chain Amyloidosis / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D061988:Proteasome Inhibitors / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D061988:Proteasome Inhibitors; D000069286:Bortezomib
keywords: Bortezomib; amyloidosis; corticosteroids; pulmonary